Tocilizumab can boost catch-up growth in systemic JIA

11/14/2012 | Family Practice News

Tocilizumab, an interleukin-6 receptor inhibitor marketed as Actemra, significantly increased the height velocities of most patients with systemic juvenile idiopathic arthritis, according to a study presented at the American College of Rheumatology meeting. Higher insulinlike growth factor-1 levels and osteocalcin/C-telopeptide of type 1 collagen ratios linked to the use of the drug suggests the treatment can benefit growth hormone axis and bone metabolism, researchers said.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD